Dr Marguerite McDonald details postop inflammation

Ophthalmology Times published a sponsored cataract surgery case discussion on October 26, 2020, featuring Dr. Marguerite McDonald on postoperative inflammation and pain control after ocular surgery. The 4-minute, 51-second video was posted in the outlet’s cataract therapeutics coverage and described the topic as management of post-operative inflammation and pain following various ocular surgeries. McDonald is listed by Ophthalmology Times as a clinical professor of ophthalmology at NYU Langone Medical Center and Tulane University Health Sciences Center, and as a physician in practice with OCLI Vision in Oceanside, New York. ### Why was this cataract segment published in the first place? The October 26, 2020 posting appeared as sponsored content by Bausch + Lomb on Ophthalmology Times’ site. The page description said viewers could “learn how experts manage post-operative inflammation and pain following various ocular surgeries,” placing the McDonald segment in a practical, treatment-focused format rather than a peer-reviewed outcomes report. (ophthalmologytimes.com) Ophthalmology Times has continued to group the video under its cataract therapeutics coverage, alongside later reports on postoperative inflammation treatments after cataract surgery. That archive placement shows the segment was presented as part of continuing clinical discussion around routine perioperative management. ### What does the case discussion actually cover? The Ophthalmology Times listing says the video focuses on managing postoperative inflammation and pain after ocular surgery. (ophthalmologytimes.com) The available page text does not provide a full transcript, but the item is explicitly framed around cataract surgery case management and therapeutic control of inflammation and pain in the postoperative period. (ophthalmologytimes.com) A separate Ophthalmology Times report on cataract postoperative care described that setting as one in which physicians weigh topical, intracameral, intracanalicular and subtenon options, and monitor for complications such as cystoid macular edema and rebound iritis. That later report was not McDonald’s segment, but it reflects the same clinical problem set the video was published to address. (ophthalmologytimes.com) ### Which point stands out most in McDonald’s appearance? McDonald’s appearance stands out because it centers on a routine but persistent cataract-surgery issue: keeping inflammation and pain controlled after an otherwise standard procedure. The Ophthalmology Times item does not publish detailed case data on the page, but its framing puts postoperative control at the center of surgical recovery. (ophthalmologytimes.com) Jesper Høiberg Erichsen, in a separate Ophthalmology Times report from the same period, said controlling postoperative inflammation is important for achieving a successful cataract outcome. That report said adding a topical steroid to an NSAID showed no benefit in his findings and that a sub-Tenon corticosteroid “dropless” approach was inferior to topical treatment. Those findings were presented separately from McDonald’s discussion, but they show why regimen choice remained an active topic in cataract care coverage. (ophthalmologytimes.com) ### How should readers treat this piece of evidence? The Ophthalmology Times page identifies the McDonald item as sponsored video content, not a randomized trial or guideline. The format is best read as a case-based clinical discussion that shows how one experienced cataract surgeon approaches postoperative inflammation and pain control. Ophthalmology Times’ author page identifies McDonald as an academic ophthalmologist with current institutional roles and private-practice affiliation, which explains why the outlet used her in educational and case-based programming. (ophthalmologytimes.com) ### Where can readers find the next step in this story? The Ophthalmology Times cataract therapeutics archive continues to publish newer items on postoperative inflammation after cataract surgery, including March 2026 coverage of clobetasol propionate ophthalmic suspension 0.05% and other therapeutic updates. (ophthalmologytimes.com) The original McDonald case discussion remains posted in that same archive for readers who want the earlier video context. (ophthalmologytimes.com 1) (ophthalmologytimes.com 2)